Brief: Trinity Biotech Announces Positive Pre-Pivotal Trial Results For Its Next-Generation Continuous Glucose Monitor Technology
07/10/2024 13:41
Oct 7 (Reuters) - Trinity Biotech PLC TRIB.O :
* TRINITY BIOTECH ANNOUNCES POSITIVE PRE-PIVOTAL TRIAL
RESULTS FOR
ITS NEXT-GENERATION CONTINUOUS GLUCOSE MONITOR TECHNOLOGY
* TRINITY BIOTECH PLC - REFINED SENSOR ACHIEVES FAVOURABLE
MARD
COMPARED TO PREVIOUS DEVICE
* TRINITY BIOTECH PLC - SECOND EUROPEAN PRE-PIVOTAL TRIAL
SCHEDULED FOR Q4 2024
Source text for Eikon: ID:nGNX73vhtt
Further company coverage: TRIB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trinity Biotech
See all newsNASDAQ RESUMED AT 12:18 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:13 PM
Brief: Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
Brief: Trinity Biotech’S Trinovium Subsidiary Agrees To Collaborate With Echelon Data Centres To Develop Advanced Liquid Cooling Solutions For Ai Infrastructure
NASDAQ RESUMED AT 09:00 AM